Joshua Hanen, OD
Optometrist · Minneapolis, MNNPI 1407293061
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $26,322 of the $40,182 with a category attached, or 65.5%. AbbVie accounts for 66.5% of it on its own, with 17 other manufacturers making up the rest. Among optometrist clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 187 payments — averaging $214.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$27K
- Sun Pharmaceutical Industries Inc.$10K
- Alcon$1K
- Maculogix, Inc.$405
- Coopervision Inc.$375
- Johnson & Johnson Vision Care, Inc.$205
- plus $844 from 12 others
What the payments were for
- Consulting fees$5,27513%
- Speaking & faculty fees$26,32266%
- Travel & lodging$5,59814%
- Food & beverage$2,9867%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 90 | $26,704 |
| Sun Pharmaceutical Industries Inc. | 17 | $10,250 |
| Alcon | 14 | $1,397 |
| Maculogix, Inc. | 12 | $405 |
| Coopervision Inc. | 10 | $375 |
| Johnson & Johnson Vision Care, Inc. | 9 | $205 |
| Glaukos Corporation | 2 | $185 |
| Oyster Point Pharma, Inc. | 9 | $145 |
| Novartis | 7 | $129 |
| Menicon America Inc | 1 | $68 |
| LKC Technologies, Inc. | 2 | $55 |
| Harrow Eye, LLC | 2 | $54 |
| Alcon Research LLC | 3 | $54 |
| Tarsus Pharmaceuticals, Inc. | 3 | $48 |
| Dompe US, Inc. | 3 | $48 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Aerie Pharmaceuticals, Inc. | 1 | $19 |
| ABB Con-cise Optical Group LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$10,059
- LUMIGAN$8,392
- RESTASIS$6,456
- COMBIGAN$5,357
- VUITY$5,250
- RESTASIS MULTIDOSE$5,213
- DAILIES$997
- AIR OPTIX$648
- AdaptDx$250
- MiSight Contact Lens$115
How this compares
$40,182 in reported general payments places this provider in the 95th percentile of 826 optometrist providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 407 | $378,986 |
| CequaCyclosporine | 336 | $247,461 |
| TyrvayaVarenicline Tartrate | 215 | $175,950 |
| Cyclosporine | 154 | $72,203 |
| LumiganBimatoprost | 102 | $56,357 |
| XiidraLifitegrast | 34 | $43,838 |
| Restasis MultidoseCyclosporine | 11 | $17,717 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 116 | $7,156 |
| Latanoprost | 216 | $4,360 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $4,153 |
| Prednisolone Acetate | 59 | $3,429 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 16 | $2,783 |
| Doxycycline Hyclate | 133 | $2,437 |
| Brimonidine Tartrate | 29 | $1,620 |
| Timolol Maleate | 81 | $1,340 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Restasis Multidose, Combigan | $26,704 | $457,213531 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $10,250 | $247,461336 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $145 | $175,950215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 826 optometrist providers in Minnesota.
Other optometrist in Minneapolis
- Sarah BaerMinneapolis$5K
- Marcie NicholsMinneapolis$4K
- Emmalee ToldoMinneapolis$3K
- Jacob LangStillwater$264K
- Britt GustafsonEden Prairie$236K
- Gina WesleyMedina$232K
- Nicholas ColatrellaSartell$84K
- Trevor FossoSartell$45K
- Mathew WalkerAlexandria$43K
- Zachary HollandEdina$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.